McDougall Jason J, Barin Ali Kursat
Department of Physiology and Biophysics, University of Calgary, 3330, Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1.
Br J Pharmacol. 2005 May;145(1):104-13. doi: 10.1038/sj.bjp.0706169.
The present study examined the peripheral effects of vasoactive intestinal peptide (VIP) on rat knee joint blood flow during acute and chronic inflammation. The involvement of joint nerves and synovial mast cells on these effects was also investigated. Prior to blood flow assessment, animals were deeply anaesthetised with ethyl carbamate (urethane; 2 mg kg(-1) i.p.). Local application of VIP (10(-13)-10(-9) mol) onto the capsular surface of normal rat knee joints caused a dose-dependent increase in synovial perfusion with an ED50 of 1.2 x 10(-11) mol. The dilator effect of the peptide was transient with the maximal response occurring approximately 1 min after drug administration. VIP-induced vasodilatation was blocked by co-administration of the VIP receptor antagonist VIP(6-28) (10(-9) mol). The inhibitory effect of the antagonist was consistent across the entire VIP dose range (P=0.01). The vasoresponsiveness to VIP was significantly attenuated in acutely inflamed joints; however, surgical denervation of acutely inflamed knees re-established the vasodilator effect of the neuropeptide. Topical application of VIP to 1- and 3-week adjuvant monoarthritic knees produced a hyperaemic response, which was not significantly different from normal (P=0.06 and 0.73 for 1- and 3-week adjuvant treated joints, respectively). Stabilisation of synovial mast cells by disodium cromoglycate (cromolyn) pretreatment did not alter the vasoresponsiveness to VIP in acute or chronically inflamed joints. The vasodilatatory effect of VIP is lost during acute knee joint inflammation and this abrogated effect is neurally dependent. In the chronic phase of knee joint inflammation, VIP-mediated hyperaemia recovers to normal levels. Synovial mast cells do not influence the vasomotor effects of exogenously applied VIP in inflamed knee joints.
本研究检测了血管活性肠肽(VIP)在急性和慢性炎症期间对大鼠膝关节血流的外周效应。还研究了关节神经和滑膜肥大细胞在这些效应中的作用。在评估血流之前,用氨基甲酸乙酯(乌拉坦;2 mg kg⁻¹腹腔注射)对动物进行深度麻醉。将VIP(10⁻¹³ - 10⁻⁹ mol)局部应用于正常大鼠膝关节的囊表面,可引起滑膜灌注呈剂量依赖性增加,半数有效剂量(ED50)为1.2×10⁻¹¹ mol。该肽的扩张作用是短暂的,最大反应在给药后约1分钟出现。联合给予VIP受体拮抗剂VIP(6 - 28)(10⁻⁹ mol)可阻断VIP诱导的血管舒张。拮抗剂的抑制作用在整个VIP剂量范围内均一致(P = 0.01)。在急性炎症关节中,对VIP的血管反应性显著减弱;然而,对急性炎症膝关节进行手术去神经支配可重新建立神经肽的血管舒张作用。将VIP局部应用于1周和3周佐剂性单关节炎膝关节可产生充血反应,与正常情况无显著差异(1周和3周佐剂治疗关节分别为P = 0.06和0.73)。通过色甘酸钠(色甘酸)预处理稳定滑膜肥大细胞,并不会改变急性或慢性炎症关节中对VIP的血管反应性。VIP的血管舒张作用在急性膝关节炎症期间丧失,且这种被消除的作用依赖于神经。在膝关节炎症的慢性期,VIP介导的充血恢复到正常水平。滑膜肥大细胞不影响外源性应用的VIP在炎症膝关节中的血管运动效应。